AIDSVAX HIV VACCINE PROGRAM:GSID'S ONLY PROGRAM SERVICE AREA IN 2024 WAS SERVING AS MANUFACTURING AND PRODUCT SPONSOR FOR ITS AIDSVAX VACCINE AND MAINTAINING A MANUFACTURING REAGENTS REPOSITORY AND CLINICAL TRIAL (PREVIOUSLY CONDUCTED) DATABASES. SINCE 2020, THE VACCINE HAS BEEN EVALUATED IN AN ONGOING PHASE 2B CLINICAL TRIAL CENTERED IN THREE SUB-SAHARAN AFRICAN COUNTRIES. FUNDING FOR GSID'S ACTIVITIES IN PRIOR YEARS WAS PROVIDED BY THE HENRY M. JACKSON FOUNDATION (BETHESDA, MD) AND THE IMPERIAL COLLEGE, LONDON (UNITED KINGDOM), THE SPONSOR OF THE AFORMENTIONED CLINICAL TRIAL.
Geographies
Not indicated
Dates
Jan 1, 2024 – Dec 31, 2024
Source
990
No causes provided
No populations provided
–
$263.9K
Program 1 [2025]
GSID CEASED OPERATIONS IN SEPTEMBER OF 2025. THIS IS THE ORGANIZATION'S FINAL 990 FILING.
